Dana-Farber/Harvard Cancer Center (DF/HCC) and Massachusetts General Hospital (MGH) Join Precision Biologics as Collaborators on Phase 2B Pancreatic Cancer Trial

Precision Biologics is pleased to announce the addition of Dana-Farber/Harvard Cancer Center (DF/HCC) and Massachusetts General Hospital (MGH) as collaborators on its ongoing Phase 2 clinical trial with its lead therapeutic compound NPC-1C (NEO-102). Thomas Jefferson University |Sidney Kimmel Cancer Center and the California Pacific Medical Center Research Institute have also joined to accrue patients to this study.

The randomized, multicenter Phase 2b clinical trial is currently accruing patients with metastatic pancreatic cancer who have progressed after front line chemotherapy with Folfirinox. The study combines second line Gemcitabine and Abraxane chemotherapy with or without NPC-1C. These new sites will be joining the current clinical sites on this multicenter study, including National Cancer Institute, Yale Cancer Center, Rutgers-Cancer Institute of New Jersey, University of Texas SouthWestern Medical Center, Washington University in St. Louis, and Duke University Medical Center in partnership with Precision Biologics.

Contacts

Precision Biologics
Press:
Sophia Lall
(c) 718-483-0735
(o) 212-414-1909
slall@rmtprmanagement.com
or
RoseMarie Terenzio
(c) 917-913-7226
(o) 212-414-1909
rterenzio@rmtprmanagement.com